# Tiragolumab

Source: https://onco.cc/drugs/tiragolumab/  
OnCo record `tiragolumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An immune-brake blocker that looked excellent in a phase 2 lung cancer trial and then failed every phase 3.

## Summary

CITYSCAPE (phase 2, 2020) showed tiragolumab plus atezolizumab roughly doubled response rate in PD-L1-high NSCLC. Phase 3 SKYSCRAPER-01 (PD-L1-high NSCLC) missed PFS and OS; SKYSCRAPER-02 (extensive-stage SCLC) was negative; SKYSCRAPER-06 (non-squamous NSCLC) was worse than control. Roche discontinued most of the programme in 2024 and 2025. Other anti-TIGIT antibodies (domvanalimab, ociperlimab) showed no clearer benefit.

Lesson: a small randomised phase 2 with a surrogate endpoint in a selected population can mislead; redundancy between checkpoints means blocking a second one does not necessarily add to PD-1/PD-L1 blockade.

## Fields

- Kind: Treatment
- Status: negative
- Last checked: 2026-09-06
- Tags: failure; lesson:phase-2-mirage
- Code: RG6058, MTIG7192A
- Modality: Monoclonal antibody (anti-TIGIT)
- Mechanism: IgG1 anti-TIGIT with intact Fc; blocks TIGIT-PVR interaction on T and NK cells.

## Sources

- Roche SKYSCRAPER-01 final analysis (2024): https://www.roche.com/media/releases/med-cor-2024-11-26

## Connected records

- pairings: [Caution: TIGIT + PD-(L)1 blockade](https://onco.cc/pairings/tigit-plus-pd1-caution/)
- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [TIGIT blockade](https://onco.cc/technologies/tigit-blockade/)
- targets: [CD155 (PVR)](https://onco.cc/targets/pvr/), [PD-L1](https://onco.cc/targets/pdl1/), [TIGIT](https://onco.cc/targets/tigit/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- trials: [A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell](https://onco.cc/trials/nct05904886/), [A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer](https://onco.cc/trials/nct05645692/), [A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li](https://onco.cc/trials/nct04524871/), [A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05009069/), [A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel](https://onco.cc/trials/nct05805501/), [NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial](https://onco.cc/trials/nct06342037/), [Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer](https://onco.cc/trials/nct04665856/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/), [Failures are hidden](https://onco.cc/bottlenecks/b-negative-results/)
- ideas: [Automatic offer of shelved cancer assets to non-profits after two years](https://onco.cc/ideas/idea-fund-shelved-asset-escrow/), [No accelerated approval for a combination without proof each part contributes](https://onco.cc/ideas/idea-tr2-contribution-of-components-mandate/)
- pathways: [NK-cell recognition: missing self & stress ligands](https://onco.cc/pathways/nk-cell-recognition/), [T-cell exhaustion](https://onco.cc/pathways/t-cell-exhaustion/)

---
JSON: https://onco.cc/api/v1/entities/tiragolumab.json